Procaps Licenses Cancer Drug

US-based company Pro-Pharmaceuticals, has granted Colombian firm Procaps exclusive rights to market and sell Davanat (carbohydrate polymer) for the treatment of advanced colorectal cancer in Colombia. The move highlights the US firm's commitment to non-traditional markets and adheres to BMI's long-term core view that emerging markets will drive industry growth.

To read the full article, please choose one of the following options: